JP2023540732A5 - - Google Patents

Info

Publication number
JP2023540732A5
JP2023540732A5 JP2023514907A JP2023514907A JP2023540732A5 JP 2023540732 A5 JP2023540732 A5 JP 2023540732A5 JP 2023514907 A JP2023514907 A JP 2023514907A JP 2023514907 A JP2023514907 A JP 2023514907A JP 2023540732 A5 JP2023540732 A5 JP 2023540732A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023514907A
Other languages
English (en)
Japanese (ja)
Other versions
JP7848189B2 (ja
JP2023540732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/072595 external-priority patent/WO2022048883A1/en
Publication of JP2023540732A publication Critical patent/JP2023540732A/ja
Publication of JP2023540732A5 publication Critical patent/JP2023540732A5/ja
Application granted granted Critical
Publication of JP7848189B2 publication Critical patent/JP7848189B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023514907A 2020-09-04 2021-08-13 抗ceacam5抗体及びコンジュゲート並びにそれらの使用 Active JP7848189B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20194711 2020-09-04
EP20194711.6 2020-09-04
EP20195559 2020-09-10
EP20195559.8 2020-09-10
PCT/EP2021/072595 WO2022048883A1 (en) 2020-09-04 2021-08-13 Anti-ceacam5 antibodies and conjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026063629A Division JP2026129730A (ja) 2020-09-04 2026-04-08 抗ceacam5抗体及びコンジュゲート並びにそれらの使用

Publications (3)

Publication Number Publication Date
JP2023540732A JP2023540732A (ja) 2023-09-26
JP2023540732A5 true JP2023540732A5 (cg-RX-API-DMAC7.html) 2024-08-21
JP7848189B2 JP7848189B2 (ja) 2026-04-20

Family

ID=77543503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514907A Active JP7848189B2 (ja) 2020-09-04 2021-08-13 抗ceacam5抗体及びコンジュゲート並びにそれらの使用

Country Status (23)

Country Link
US (1) US20250122282A2 (cg-RX-API-DMAC7.html)
EP (2) EP4725500A3 (cg-RX-API-DMAC7.html)
JP (1) JP7848189B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230062600A (cg-RX-API-DMAC7.html)
CN (1) CN116113439A (cg-RX-API-DMAC7.html)
AU (1) AU2021335257A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001733A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190586A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023000630A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023004252A2 (cg-RX-API-DMAC7.html)
DK (1) DK4208481T3 (cg-RX-API-DMAC7.html)
ES (1) ES3075664T3 (cg-RX-API-DMAC7.html)
FI (1) FI4208481T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260730T1 (cg-RX-API-DMAC7.html)
IL (1) IL301004A (cg-RX-API-DMAC7.html)
LT (1) LT4208481T (cg-RX-API-DMAC7.html)
MX (1) MX2023002330A (cg-RX-API-DMAC7.html)
PH (1) PH12023550266A1 (cg-RX-API-DMAC7.html)
PL (1) PL4208481T3 (cg-RX-API-DMAC7.html)
RS (1) RS68154B1 (cg-RX-API-DMAC7.html)
SI (1) SI4208481T1 (cg-RX-API-DMAC7.html)
TW (1) TW202212362A (cg-RX-API-DMAC7.html)
WO (1) WO2022048883A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
US12605459B2 (en) 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
JP7904824B2 (ja) * 2020-09-15 2026-08-13 シンアフィックス ビー.ブイ. 抗体-エクサテカンコンジュゲート
MX2024008640A (es) * 2022-01-12 2024-07-24 Regeneron Pharma Analogos de camptotecina conjugados a un residuo de glutamina en una proteina y su uso.
CN119604314A (zh) * 2022-03-09 2025-03-11 默克专利有限公司 抗gd2抗体、免疫偶联物及其治疗用途
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
WO2024108053A1 (en) * 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
TW202434306A (zh) * 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 抗cea抗體藥物軛合物及使用方法
EP4410313A1 (en) 2023-01-31 2024-08-07 Synaffix B.V. Homogeneous antibody-conjugates with high payload loading
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
WO2024231224A2 (en) 2023-05-05 2024-11-14 BioNTech SE Antibody-drug conjugates employing novel linker-payload systems for enhanced targeting of cancer-associated antigens
EP4705354A1 (en) * 2023-06-05 2026-03-11 Nona Biosciences (Suzhou) Co., Ltd. Anti-ceacam5 antibodies
CN122206704A (zh) * 2023-11-09 2026-06-12 多安生物治疗有限公司 抗ceacam5抗体及其用途
US20250186604A1 (en) * 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody conjugates
AU2024407717A1 (en) * 2023-12-22 2026-08-06 Affinity (Shanghai) Biopharmaceutical Co., Ltd. Tumor microenvironment-activated drug conjugate and antibody-drug conjugate
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025214479A1 (en) 2024-04-12 2025-10-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ceacam5 binding protein and use thereof
WO2025242099A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技(成都)有限公司 针对cdh17的抗体偶联药物及其用途
WO2025242091A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技(成都)有限公司 针对ceacam5的抗体及其用途
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技(成都)有限公司 针对ceacam5的抗体偶联药物及其用途
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2026012312A1 (en) 2024-07-09 2026-01-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-ceacam5 antibody-drug conjugate and method for preparation and use thereof
WO2026052013A1 (zh) * 2024-09-05 2026-03-12 北京泰德制药股份有限公司 一种抗ceacam5抗体及其应用
WO2026087510A2 (en) 2024-10-21 2026-04-30 Merck Patent Gmbh Pharmaceutical compositions containing stabilized antibody-drug conjugates
WO2026107136A1 (en) * 2024-11-14 2026-05-21 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates for the treatment of cancer
WO2026108676A1 (en) * 2024-11-25 2026-05-28 Wuxi Biologics (Shanghai) Co., Ltd. Anti-ceacam5 antibodies, adcs and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US244A (en) 1837-06-30 Edward flint
US5204A (en) 1847-07-24 james cantelo
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001522241A (ja) 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ 診断方法および試薬
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
EP2195023B1 (en) 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2011034660A1 (en) * 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
US9492566B2 (en) * 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
KR102019913B1 (ko) * 2017-03-24 2019-09-09 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도

Similar Documents

Publication Publication Date Title
CN107849148B (zh) 三特异性结合蛋白质及使用方法
JP4294596B2 (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
JP2022180379A5 (cg-RX-API-DMAC7.html)
JP2025090743A5 (cg-RX-API-DMAC7.html)
JP2022553324A5 (cg-RX-API-DMAC7.html)
JP2022543070A5 (cg-RX-API-DMAC7.html)
JP2016519932A5 (cg-RX-API-DMAC7.html)
JP2020519643A5 (cg-RX-API-DMAC7.html)
EA200700136A1 (ru) Анти-cd154-антитела
JP2007526880A5 (cg-RX-API-DMAC7.html)
JP2020530285A5 (cg-RX-API-DMAC7.html)
JP2008541711A5 (cg-RX-API-DMAC7.html)
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
NO20063026L (no) Antistoffer
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
JP2020516603A5 (cg-RX-API-DMAC7.html)
JP2017512825A5 (cg-RX-API-DMAC7.html)
PH12022551828A1 (en) Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
JP2022513331A5 (cg-RX-API-DMAC7.html)
JP2018535972A5 (cg-RX-API-DMAC7.html)
PE20240369A1 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y metodos de uso de estos
JP2024522164A5 (cg-RX-API-DMAC7.html)
WO2023280297A9 (zh) Cd19抗体及其应用
Dunn et al. Fine mapping of the binding sites of monoclonal antibodies raised against the Pk tag